Evidence map›Paper›PMID 35622144›Full record

ArticleVirchows Archiv : an international journal of pathology2022

Towards a national strategy for digital pathology in Switzerland.

Andrew Janowczyk, Daniel Baumhoer, Stefan Dirnhofer, Rainer Grobholz, Anja Kipar, Laurence de Leval, Doron Merkler, Olivier Michielin, Holger Moch, Aurel Perren and 8 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Digital Pathology in Hematopathology: From Vision to Deployment.International journal of laboratory hematology · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 7 institutions in 2 countries.

Andrew JanowczykDepartment of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Daniel BaumhoerInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Stefan DirnhoferInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Rainer GrobholzMedical Faculty, University of Zurich, Zurich, Switzerland.
Anja KiparInstitute of Veterinary Pathology, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.
Laurence de LevalInstitute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
Doron MerklerDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Olivier MichielinDepartment of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Holger MochDepartment of Pathology and Molecular Pathology, University of Zurich and University Hospital Zurich, Raemistrasse 100, CH-8091, Zurich, Switzerland.
Aurel PerrenInstitute of Pathology, University of Bern, Murtenstrasse 31, CH-3008, Bern, Switzerland.
Sven RottenbergInstitute of Animal Pathology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
Laura Rubbia-BrandtDepartment of Pathology and Immunology, University of Geneva, Geneva, Switzerland.
Mark A RubinBern Center for Precision Medicine, University of Bern, Bern, Switzerland.
Christine SempouxInstitute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland.
Markus TolnayInstitute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
Inti ZlobecInstitute of Pathology, University of Bern, Murtenstrasse 31, CH-3008, Bern, Switzerland. inti.zlobec@pathology.unibe.ch.
Viktor Hendrik KoelzerMedical Faculty, University of Zurich, Zurich, Switzerland. viktor.koelzer@usz.ch.ORCID http://orcid.org/0000-0001-9206-4885
Swiss Digital Pathology Consortium (SDiPath)
University of Bern · CHUniversity of Zurich · CHUniversity of Basel · CHUniversity of Geneva · CHUniversity of Lausanne · CHCase Western Reserve University · USSIB Swiss Institute of Bioinformatics · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Precision medicine is entering a new era of digital diagnostics; the availability of integrated digital pathology (DP) and structured clinical datasets has the potential to become a key catalyst for biomedical research, education and business development. In Europe, national programs for sharing of this data will be crucial for the development, testing, and validation of machine learning-enabled tools supporting clinical decision-making. Here, the Swiss Digital Pathology Consortium (SDiPath) discusses the creation of a Swiss Digital Pathology Infrastructure (SDPI), which aims to develop a unified national DP network bringing together the Swiss Personalized Health Network (SPHN) with Swiss university hospitals and subsequent inclusion of cantonal and private institutions. This effort builds on existing developments for the national implementation of structured pathology reporting. Opening this national infrastructure and data to international researchers in a sequential rollout phase can enable the large-scale integration of health data and pooling of resources for research purposes and clinical trials. Therefore, the concept of a SDPI directly synergizes with the priorities of the European Commission communication on the digital transformation of healthcare on an international level, and with the aims of the Swiss State Secretariat for Economic Affairs (SECO) for advancing research and innovation in the digitalization domain. SDPI directly addresses the needs of existing national and international research programs in neoplastic and non-neoplastic diseases by providing unprecedented access to well-curated clinicopathological datasets for the development and implementation of novel integrative methods for analysis of clinical outcomes and treatment response. In conclusion, a SDPI would facilitate and strengthen inter-institutional collaboration in technology, clinical development, business and research at a national and international scale, promoting improved patient care via precision medicine.

Indexed as

Biomedical ResearchEuropeHumansMachine LearningPrecision MedicineSwitzerlandArtificial intelligenceBiomedical researchImage analysisPathologyPrecision medicine

Identifiers

PMID35622144
PMCPMC9534807
OpenAlexW4281717113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.